Ryo Kurosawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryo Kurosawa has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Akane Yumoto
Space Environment Utilization Center, Human Spaceflight Technology Directorate, Japan Aerospace Exploration Agency (JAXA), Ibaraki 305-8505, Japan
1 shared publication- Akihito Otsuki
Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan
1 shared publication Ayana Matsumoto
Department of Clinical Physiology, Tohoku University Graduate School of Medicine, Sendai, Japan
1 shared publication- Changhoon Kim
Bioinformatics Institute, Macrogen Inc., Seoul 08511, Republic of Korea
1 shared publication - Charles A. Fuller
Department of Neurobiology, Physiology and Behavior, University of California, Davis, CA, USA
1 shared publication - Chikashi Terao
Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (4) , e005341
Machine Learning Reveals the Contribution of Rare Genetic Variants and Enhances Risk Prediction for Coronary Artery Disease in the Japanese Population
BACKGROUND: GWASs (genome-wide association studies) have advanced our understanding of coronary artery disease (CAD) genetics and enabled the development of polygenic risk scores (PRSs) for estimating genetic risk based on common variant burden. However, GWASs have limitations in analyzing rare variants due to insufficient statistical power, thereby constraining PRS performance. METHODS: We conducted whole-genome sequencing of 1752 Japanese patients with CAD and 3019 controls. A machine learning-based analytical framework was applied to identify and interpret rare genetic variants associated with CAD pathogenesis. RESULTS: This approach identified 59 CAD-related genes, including known causal genes such as LDLR and those not previously captured by GWASs. A rare variant-based risk score derived from the framework demonstrated distinct clinical characteristics compared with a conventional common variant-based PRS. The rare variant-based risk score significantly discriminated CAD cases and predicted cardiovascular mortality in an independent cohort. Furthermore, combining the rare variant-based risk score with the traditional PRS improved CAD prediction compared with the PRS alone (area under the curve, 0.66 versus 0.61; P =0.007). CONCLUSIONS: These findings underscore the distinct and complementary value of the rare variant-based risk score compared with the conventional PRS, highlighting the enhanced predictive power achieved through their integration. This comprehensive approach proposes broader genetic profiling, offering substantial potential for improved clinical risk stratification and personalized prevention strategies.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (4) , e005341
Open AccessMachine Learning Reveals the Contribution of Rare Genetic Variants and Enhances Risk Prediction for Coronary Artery Disease in the Japanese Population
BACKGROUND: GWASs (genome-wide association studies) have advanced our understanding of coronary artery disease (CAD) genetics and enabled the development of polygenic risk scores (PRSs) for estimating genetic risk based on common variant burden. However, GWASs have limitations in analyzing rare variants due to insufficient statistical power, thereby constraining PRS performance. METHODS: We conducted whole-genome sequencing of 1752 Japanese patients with CAD and 3019 controls. A machine learning-based analytical framework was applied to identify and interpret rare genetic variants associated with CAD pathogenesis. RESULTS: This approach identified 59 CAD-related genes, including known causal genes such as LDLR and those not previously captured by GWASs. A rare variant-based risk score derived from the framework demonstrated distinct clinical characteristics compared with a conventional common variant-based PRS. The rare variant-based risk score significantly discriminated CAD cases and predicted cardiovascular mortality in an independent cohort. Furthermore, combining the rare variant-based risk score with the traditional PRS improved CAD prediction compared with the PRS alone (area under the curve, 0.66 versus 0.61; P =0.007). CONCLUSIONS: These findings underscore the distinct and complementary value of the rare variant-based risk score compared with the conventional PRS, highlighting the enhanced predictive power achieved through their integration. This comprehensive approach proposes broader genetic profiling, offering substantial potential for improved clinical risk stratification and personalized prevention strategies.
- Open Access
- 13 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (11) , eaed2258
0.33 g mitigates muscle atrophy while 0.67 g preserves muscle function and myofiber type composition in mice during spaceflight
As human space exploration advances, understanding how different gravity levels affect skeletal muscle is critical for long-term health. Among the major organ systems, skeletal muscle is particularly sensitive to gravitational unloading, yet the gravity threshold required to maintain homeostasis remains unclear. Using the Multiple Artificial-gravity Research System aboard the International Space Station, mice were exposed to graded gravity levels, microgravity, 0.33 g , 0.67 g , and 1 g , and their muscles were analyzed postflight. In the gravity-sensitive soleus, the cross-sectional area was preserved at 0.33 g , while the slow-to-fast myofiber transition was partially suppressed at 0.33 g and fully prevented at 0.67 g . Functional measures, including forelimb grip strength and electrical impedance myography, indicated that 0.67 g was sufficient to maintain muscle performance. Plasma metabolomics identified 11 metabolites with gravity-dependent changes, suggesting potential biomarkers for monitoring physiological adaptation. Collectively, these results identify 0.67 g as a critical threshold for mitigating spaceflight-induced muscle atrophy and myofiber type transitions.
- 13 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (11) , eaed2258
Open Access0.33 g mitigates muscle atrophy while 0.67 g preserves muscle function and myofiber type composition in mice during spaceflight
As human space exploration advances, understanding how different gravity levels affect skeletal muscle is critical for long-term health. Among the major organ systems, skeletal muscle is particularly sensitive to gravitational unloading, yet the gravity threshold required to maintain homeostasis remains unclear. Using the Multiple Artificial-gravity Research System aboard the International Space Station, mice were exposed to graded gravity levels, microgravity, 0.33 g , 0.67 g , and 1 g , and their muscles were analyzed postflight. In the gravity-sensitive soleus, the cross-sectional area was preserved at 0.33 g , while the slow-to-fast myofiber transition was partially suppressed at 0.33 g and fully prevented at 0.67 g . Functional measures, including forelimb grip strength and electrical impedance myography, indicated that 0.67 g was sufficient to maintain muscle performance. Plasma metabolomics identified 11 metabolites with gravity-dependent changes, suggesting potential biomarkers for monitoring physiological adaptation. Collectively, these results identify 0.67 g as a critical threshold for mitigating spaceflight-induced muscle atrophy and myofiber type transitions.
- 19 July 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (5) , 1325-1338
Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction
Aims: Heart failure with preserved left ventricular ejection fraction (HFpEF) is a serious health problem worldwide, as no effective therapy is yet available. We have previously demonstrated that our low-intensity pulsed ultrasound (LIPUS) therapy is effective and safe for angina and dementia. In this study, we aimed to examine whether the LIPUS therapy also ameliorates cardiac diastolic dysfunction in mice. Methods and results: Twelve-week-old obese diabetic mice (db/db) and their control littermates (db/+) were treated with either the LIPUS therapy [1.875 MHz, 32 cycles, Ispta (spatial peak temporal average intensity) 117–162 mW/cm2, 0.25 W/cm2] or placebo procedure two times a week for 4 weeks. At 20-week-old, transthoracic echocardiography and invasive haemodynamic analysis showed that cardiac diastolic function parameters, such as e′, E/e′, end-diastolic pressure–volume relationship, Tau, and dP/dt min, were all deteriorated in placebo-treated db/db mice compared with db/+ mice, while systolic function was preserved. Importantly, these cardiac diastolic function parameters were significantly ameliorated in the LIPUS-treated db/db mice. We also measured the force (F) and intracellular Ca2+ ([Ca2+]i) in trabeculae dissected from ventricles. We found that relaxation time and [Ca2+]i decay (Tau) were prolonged during electrically stimulated twitch contractions in db/db mice, both of which were significantly ameliorated in the LIPUS-treated db/db mice, indicating that the LIPUS therapy also improves relaxation properties at tissue level. Functionally, exercise capacity was also improved in the LIPUS-treated db/db mice. Histologically, db/db mice displayed progressed cardiomyocyte hypertrophy and myocardial interstitial fibrosis, while those changes were significantly suppressed in the LIPUS-treated db/db mice. Mechanistically, western blot showed that the endothelial nitric oxide synthase (eNOS)-nitric oxide (NO)-cGMP-protein kinase G (PKG) pathway and Ca2+-handling molecules were up-regulated in the LIPUS-treated heart. Conclusions: These results indicate that the LIPUS therapy ameliorates cardiac diastolic dysfunction in db/db mice through improvement of eNOS-NO-cGMP-PKG pathway and cardiomyocyte Ca2+-handling system, suggesting its potential usefulness for the treatment of HFpEF patients.
- 19 July 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (5) , 1325-1338
Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction
Aims: Heart failure with preserved left ventricular ejection fraction (HFpEF) is a serious health problem worldwide, as no effective therapy is yet available. We have previously demonstrated that our low-intensity pulsed ultrasound (LIPUS) therapy is effective and safe for angina and dementia. In this study, we aimed to examine whether the LIPUS therapy also ameliorates cardiac diastolic dysfunction in mice. Methods and results: Twelve-week-old obese diabetic mice (db/db) and their control littermates (db/+) were treated with either the LIPUS therapy [1.875 MHz, 32 cycles, Ispta (spatial peak temporal average intensity) 117–162 mW/cm2, 0.25 W/cm2] or placebo procedure two times a week for 4 weeks. At 20-week-old, transthoracic echocardiography and invasive haemodynamic analysis showed that cardiac diastolic function parameters, such as e′, E/e′, end-diastolic pressure–volume relationship, Tau, and dP/dt min, were all deteriorated in placebo-treated db/db mice compared with db/+ mice, while systolic function was preserved. Importantly, these cardiac diastolic function parameters were significantly ameliorated in the LIPUS-treated db/db mice. We also measured the force (F) and intracellular Ca2+ ([Ca2+]i) in trabeculae dissected from ventricles. We found that relaxation time and [Ca2+]i decay (Tau) were prolonged during electrically stimulated twitch contractions in db/db mice, both of which were significantly ameliorated in the LIPUS-treated db/db mice, indicating that the LIPUS therapy also improves relaxation properties at tissue level. Functionally, exercise capacity was also improved in the LIPUS-treated db/db mice. Histologically, db/db mice displayed progressed cardiomyocyte hypertrophy and myocardial interstitial fibrosis, while those changes were significantly suppressed in the LIPUS-treated db/db mice. Mechanistically, western blot showed that the endothelial nitric oxide synthase (eNOS)-nitric oxide (NO)-cGMP-protein kinase G (PKG) pathway and Ca2+-handling molecules were up-regulated in the LIPUS-treated heart. Conclusions: These results indicate that the LIPUS therapy ameliorates cardiac diastolic dysfunction in db/db mice through improvement of eNOS-NO-cGMP-PKG pathway and cardiomyocyte Ca2+-handling system, suggesting its potential usefulness for the treatment of HFpEF patients.